Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Oncological Medicine
Volume 2015, Article ID 123756, 5 pages
http://dx.doi.org/10.1155/2015/123756
Case Report

Denileukin Diftitox (Ontak) as Maintenance Therapy for Peripheral T-Cell Lymphomas: Three Cases with Sustained Remission

1Department of Internal Medicine, University of Florida, Gainesville, FL 32610, USA
2Division of Hematology/Oncology, Department of Internal Medicine, University of Florida, Gainesville, FL 32610, USA
3Florida Cancer Specialists and Research Institute, Leesburg, FL 34748, USA

Received 31 March 2015; Revised 25 June 2015; Accepted 5 July 2015

Academic Editor: Guido Fadda

Copyright © 2015 Alejandra C. Fuentes et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. American Cancer Society, Cancer Facts and Figures 2015, American Cancer Society, Atlanta, Ga, USA, 2015, http://www.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2015/index.
  2. N. L. Harris, E. S. Jaffe, H. Stein et al., “A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group,” Blood, vol. 84, no. 5, pp. 1361–1392, 1994. View at Google Scholar · View at Scopus
  3. L. Karlin and B. Coiffier, “The changing landscape of peripheral T-cell lymphoma in the era of novel therapies,” Seminars in Hematology, vol. 51, no. 1, pp. 25–34, 2014. View at Publisher · View at Google Scholar · View at Scopus
  4. N. M. Reddy and A. M. Evens, “Chemotherapeutic advancements in peripheral T-cell lymphoma,” Seminars in Hematology, vol. 51, no. 1, pp. 17–24, 2014. View at Publisher · View at Google Scholar · View at Scopus
  5. M. P. Escalón, N. S. Liu, Y. Yang et al., “Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: the M. D. Anderson Cancer Center experience,” Cancer, vol. 103, no. 10, pp. 2091–2098, 2005. View at Publisher · View at Google Scholar · View at Scopus
  6. N. H. Dang, B. Pro, F. B. Hagemeister et al., “Phase II trial of denileukin diftitox for relapsed/refractory T-cell non-Hodgkin lymphoma,” British Journal of Haematology, vol. 136, no. 3, pp. 439–447, 2007. View at Publisher · View at Google Scholar · View at Scopus
  7. B. Y. Wong, S. A. Gregory, and N. H. Dang, “Denileukin diftitox as novel targeted therapy for lymphoid malignancies,” Cancer Investigation, vol. 25, no. 6, pp. 495–501, 2007. View at Publisher · View at Google Scholar · View at Scopus
  8. N. H. Dang, F. B. Hagemeister, B. Pro et al., “Phase II study of denileukin diftitox for relapsed/refractory B-cell non-Hodgkin's lymphoma,” Journal of Clinical Oncology, vol. 22, no. 20, pp. 4095–4102, 2004. View at Publisher · View at Google Scholar · View at Scopus
  9. B. Y. Wong, Y. Ma, R. Fitzwilson, and N. H. Dang, “De novo maintenance therapy with denileukin diftitox (Ontak) in a patient with peripheral T-cell lymphoma is associated with prolonged remission,” American Journal of Hematology, vol. 83, no. 7, pp. 596–598, 2008. View at Publisher · View at Google Scholar · View at Scopus
  10. V. Mak, J. Hamm, M. Chhanabhai et al., “Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors,” Journal of Clinical Oncology, vol. 31, no. 16, pp. 1970–1976, 2013. View at Publisher · View at Google Scholar · View at Scopus
  11. C. E. Dearden and F. M. Foss, “Peripheral T-cell lymphomas: diagnosis and management,” Hematology/Oncology Clinics of North America, vol. 17, no. 6, pp. 1351–1366, 2003. View at Publisher · View at Google Scholar · View at Scopus
  12. M. Jagasia, D. Morgan, S. Goodman et al., “Histology impacts the outcome of peripheral T-cell lymphomas after high dose chemotherapy and stem cell transplant,” Leukemia and Lymphoma, vol. 45, no. 11, pp. 2261–2267, 2004. View at Publisher · View at Google Scholar · View at Scopus
  13. N. Mounier, C. Gisselbrecht, J. Briere et al., “All aggressive lymphoma subtypes do not share similar outcome after front-line autotransplantation: A matched-control analysis by the Groupe d'Etude des Lymphomes de l'Adulte (GELA),” Annals of Oncology, vol. 15, no. 12, pp. 1790–1797, 2004. View at Google Scholar
  14. K. W. Zamkoff, M. D. Matulis, A. C. Mehta, M. W. Beaty, R. E. Hutchison, and T. C. Gentile, “High-dose therapy and autologous stem cell transplant does not result in long-term disease-free survival in patients with recurrent chemotherapy-sensitive ALK-negative anaplastic large-cell lymphoma,” Bone Marrow Transplantation, vol. 33, no. 6, pp. 635–638, 2004. View at Publisher · View at Google Scholar · View at Scopus
  15. F. M. Foss, N. Sjak-Shie, A. Goy et al., “A multicenter phase II trial to determine the safety and efficacy of combination therapy with denileukin diftitox and cyclophosphamide, doxorubicin, vincristine and prednisone in untreated peripheral T-cell lymphoma: the CONCEPT study,” Leukemia and Lymphoma, vol. 54, no. 7, pp. 1373–1379, 2013. View at Publisher · View at Google Scholar · View at Scopus
  16. J. O. Armitage, “The aggressive peripheral T-cell lymphomas: 2013,” American Journal of Hematology, vol. 88, no. 10, pp. 910–918, 2013. View at Publisher · View at Google Scholar · View at Scopus
  17. S. Spranger and T. Gajewski, “Rational combinations of immunotherapeutics that target discrete pathways,” Journal for ImmunoTherapy of Cancer, vol. 1, article 16, 2013. View at Publisher · View at Google Scholar
  18. J. Kline, I. E. Brown, Y.-Y. Zha et al., “Homeostatic proliferation plus regulatory T-cell depletion promotes potent rejection of B16 melanoma,” Clinical Cancer Research, vol. 14, no. 10, pp. 3156–3167, 2008. View at Publisher · View at Google Scholar · View at Scopus
  19. A. J. Rech and R. H. Vonderheide, “Clinical use of anti-CD25 antibody daclizumab to enhance immune responses to tumor antigen vaccination by targeting regulatory T cells,” Annals of the New York Academy of Sciences, vol. 1174, pp. 99–106, 2009. View at Publisher · View at Google Scholar · View at Scopus
  20. R. P. M. Sutmuller, L. M. van Duivenvoorde, A. van Elsas et al., “Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25+ regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses,” The Journal of Experimental Medicine, vol. 194, no. 6, pp. 823–832, 2001. View at Publisher · View at Google Scholar · View at Scopus